News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
2/7/2020
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC

2/7/2020

CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments f...

 Continue Reading
1/10/2020
8:00 AM ET
Press Release

Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors

1/10/2020

CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company developi...

 Continue Reading
12/13/2019
2:07 PM ET
Press Release

Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market

12/13/2019

CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously...

 Continue Reading
12/12/2019
9:54 AM ET
Press Release

CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

12/12/2019

CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), please note that the pricing and f...

 Continue Reading
12/12/2019
8:00 AM ET
Press Release

Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

12/12/2019

CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN). (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into defi...

 Continue Reading
12/10/2019
4:00 PM ET
Press Release

Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients

12/10/2019

CHARLOTTESVILLE, Va., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
11/19/2019
4:05 PM ET
Press Release

Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

11/19/2019

CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
Displaying 1 to 7 (of 126 releases)